ANI Pharmaceuticals Inc (ANIP) stock
Close on Nov 12, 2026Market cap $1.63BP/E 13.4Yield –
ANI Pharmaceuticals Inc grew revenue 25.9% to $1.04B over the twelve months to Sep 30, 2026. Operating income rose 131.4% to $166.49M, moving the operating margin from 8.7% to 16.0%. Free cash flow was $205.32M, up 31.8% from a year earlier. At the latest close the market valued the company at $1.63B, 13.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.63B
- P/E ratio
- 13.4
- Price to sales
- 1.57
- Price to book
- 2.56
- Dividend yield
- –
- Free cash flow yield
- 12.58%
Fundamentals
- Revenue
- $1.04B
- Net income
- $116.84M
- EPS, diluted
- $5.30
- Free cash flow
- $205.32M
- Book value per share
- $29.39
- Diluted shares
- 22M
Trading
- Next earnings
- Feb 26, 2027 (estimated, before the open)
- Previous close
- $71.09
- Open
- $71.56
- Day's range
- $70.00 – $71.82
- Volume
- 361,301
- Average volume (20 days)
- 474,006
- Index membership
- S&P SmallCap 600, Russell 2000, Russell 3000
- Beta (5 years)
- 0.61
- 52-week range
- $67.14 – $89.57
- RSI (14 days)
- 48.4
- Volatility (1 year)
- 31.9%
- Relative volume
- 0.92×
- WACC
- 7.9%
On 3 of our idea lists: Undervalued and financially sound, Small-cap growth, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANIP | S&P 500 | Difference | ANIP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.4% | -2.7% | −0.7 pts | ||
| 3 months | -5.4% | -1.7% | −3.7 pts | ||
| Year to date | -10.0% | +11.9% | −21.9 pts | ||
| 1 year | -18.6% | +12.0% | −30.6 pts | ||
| 3 years | +36.2% | +78.2% | −41.9 pts | +10.9% | +21.2% |
| 5 years | +56.0% | +73.2% | −17.3 pts | +9.3% | +11.6% |
| 10 years | +23.4% | +309.6% | −286.2 pts | +2.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ANI Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- Results
- Results
- Results
About ANI Pharmaceuticals
Pharmaceutical Preparations
ANI Pharmaceuticals is a biopharmaceutical company that develops, produces, and commercializes therapeutic medications. Its operations comprise rare disease, generic, and branded pharmaceutical segments. The company's portfolio features key therapies such as Cortrophin Gel for chronic autoimmune conditions, ophthalmic treatments ILUVIEN and YUTIQ, and over 120 generic drugs spanning diverse indications, alongside established branded pharmaceuticals. Its products serve patients with specialized or rare disorders, individuals requiring generic medicines, and healthcare professionals across multiple medical specialties.
Company profile, executives and historyANI Pharmaceuticals stock: common questions
What is ANI Pharmaceuticals's stock price?
ANIP closed at $71.06 on Nov 12, 2026, down 0.04% on the day. Over the past 52 weeks it traded between $67.14 and $89.57.
What is ANI Pharmaceuticals's market cap?
ANI Pharmaceuticals was worth $1.63B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ANIP's P/E ratio?
ANIP trades at 13.4 times earnings, based on diluted earnings per share of $5.30 over the twelve months to Sep 30, 2026.
How much revenue does ANI Pharmaceuticals make?
ANI Pharmaceuticals reported revenue of $1.04B for the twelve months to Sep 30, 2026, up 25.9% from a year earlier.
Does ANI Pharmaceuticals pay a dividend?
No. ANI Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does ANI Pharmaceuticals report earnings next?
ANI Pharmaceuticals is expected to report Q4 FY2026 results on Feb 26, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ANIP stock performed over the past year?
Including dividends, ANIP returned -18.6% over the past year, against +12.0% for the S&P 500.
How many ANIP shares are sold short?
4M shares were sold short at the latest FINRA report, 17.78% of the float, or 11.9 days of average trading volume.
Who are ANI Pharmaceuticals's competitors?
Companies most similar to ANI Pharmaceuticals by business, industry and size include ACAD, AMRX, KNSA, INSM, ASND.
See a number that looks wrong?